Clinical trials: Klatskin's Tumor
Unresectable Hilar Cholangiocarcinoma
REMS Combined With TAI for Unresectable HC
The purpose of this randomized controlled study is to evaluate the efficacy and safety of the Radiation-Emitting Metallic Stents (REMS) combined with Trans-Arterial Infusion (TAI) for unresectable hilar cholangiocarcinoma.
- Trial name
- NCT04801160
- Testing
- REMS+TAI, SEMS+TAI
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Zhongda Hospital
Cholangiocarcinoma, Klatskin Tumor
Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)
The purpose of this study is to test the safety of giving external beam radiation, followed by a Cyberknife radiosurgery boost at different dose levels, together with a chemotherapy drug called capecitabine.
- Conditions
- Cholangiocarcinoma, Klatskin Tumor, Biliary Tract Cancer
- Trial name
- NCT00630890
- Testing
- External beam radiation and Cyberknife radiosurgery boost and capecitabine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of California, San Francisco
Biliary Tract Neoplasms, Cholangiocarcinoma, Intrahepatic
Safety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer
BTC-Ag-T (ACH-AgT001) is an autologous experimental T-cell therapy designed for advanced biliary tract cancer. This is an open-label, single-arm Phase 1 study to evaluate the safety, tolerability, and preliminary efficacy of…
- Conditions
- Biliary Tract Neoplasms, Cholangiocarcinoma, Intrahepatic, Cholangiocarcinoma, Extrahepatic, Cholangiocarcinoma, Perihilar
- Trial name
- NCT07614061
- Testing
- BTC-Ag-T (ACH-AgT001), Cyclophosphamide and Fludarabine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Zhongshan Hospital
Hilar Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma
Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma
The goal of this observational cohort study is to assess the yield of preoperative endoscopic ultrasound focussed on lymph nodes in patients with presumed resectable perihilar (pCCA), intrahepatic (iCCA) or mid-common bile duct…
- Conditions
- Hilar Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma, Common Bile Duct Neoplasms, Cholangiocarcinoma
- Trial name
- POELH-II (NCT05678218)
- Testing
- Endoscopic Ultrasound registration
- Where
- 7 sites in Belgium, Netherlands
- Volunteers
- 245 people
- Sponsor
- Erasmus Medical Center
Hilar Cholangiocarcinoma
I-125 Seeds Loaded Stent Insertion for Inoperable Hilar Cholangiocarcinoma
Malignant biliary obstruction usually arise in patients suffering from primary or metastatic hepatobiliary tumors. Approximately 80% of malignant biliary obstruction patients are not eligible for surgical resection, and as such…
- Trial name
- NCT04779788
- Testing
- I-125 seeds loaded stent (self-expanded metal stent with I-125 seeds, Micro-Tech, Nanjing, China), Normal stent (self-expanded metal stent without I-125 seeds, Micro-Tech, Nanjing, China)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Xuzhou Central Hospital
Hilar Cholangiocarcinoma
MRI-based Clinico-radiomics Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma
This is a prospective, observational diagnostic study aiming to assess multiparametric MRI-based clinico-radiomics for identifying lymph node metastasis status in hilar cholangiocarcinoma.
- Trial name
- NCT05626127
- Testing
- No interventions
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Perihilar Cholangiocarcinoma
PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma
This is an open-label,single center,non-randomized,single arm exploratory study. The objective of this study is to evaluate the efficacy and safety of PD-1 antibody plus GEMOX as postoperative adjuvant therapy in perihilar…
- Trial name
- NCT05430698
- Testing
- PD-1antibody plus GEMOX
- Where
- China
- Volunteers
- 62 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer
This is an interventional, prospective multicenter, open-label, phase II study in patients after curative surgery for BTC in a classic adjuvant situation, consisting of a two arm feasibility pilot part with a randomized…
- Conditions
- Biliary Tract Cancer (CCA), Intrahepatic Cholangiocarcinoma, Hilar Cholangiocarcinoma, Distal Cholangiocarcinoma
- Trial name
- NCT05239169
- Testing
- Durvalumab, Tremelimumab, Capecitabine
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Carcinoma, Fibrolamellar Hepatocellular Carcinoma
Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards
The goal of this observational study is to compare the recommendations of the artificial intelligence clinical decision support system 'ADBoard', with the recommendations of physicians by tumor conferences in patients with…
- Conditions
- Hepatocellular Carcinoma, Fibrolamellar Hepatocellular Carcinoma, Cholangiocarcinoma, Perihilar, Intrahepatic Cholangiocarcinoma
- Trial name
- ADBoard (NCT05681949)
- Testing
- ADBoard
- Where
- Germany
- Volunteers
- 1,200 people
- Sponsor
- Charite University, Berlin, Germany
Cholangiocarcinoma
The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma
The purpose of this project is to evaluate the role of gadoxetate (Eovist®) enhanced dual-energy CT in better evaluating perihilar cholangiocarcinoma.
- Trial name
- NCT01673802
- Testing
- CT scan
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Alabama at Birmingham
Biliary Tract Cancer, Cholangiocarcinoma
Feasibility Study of Multi-Platform Profiling of Resected Biliary Tract Cancer
This study is going to test the ability to successfully obtain results from certain personalized tests for patients with biliary tract cancers that are able to be surgically removed.
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Gallbladder Cancer, Intrahepatic Cholangiocarcinoma
- Trial name
- NCT04561453
- Testing
- Multi-Platform Profiling with Organoid Drug Sensitivity Screening and ctDNA Monitoring
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Washington
Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma
Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)
This phase II ComboMATCH treatment trial compares the usual treatment of modified leucovorin, fluorouracil and oxaliplatin (mFOLFOX6) chemotherapy to using binimetinib plus mFOLFOX6 chemotherapy to shrink tumors in patients with…
- Conditions
- Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma, Recurrent Biliary Tract Carcinoma
- Trial name
- NCT05564403
- Testing
- Binimetinib, Biopsy Procedure, Biospecimen Collection
- Where
- 207 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Hepatobiliary Cancer, Pancreatic Cancer
Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer
The worldwide incidence of hepatobiliary and pancreatic (HPB) cancers is dramatically increasing especially for pancreatic cancer. Increasing age is associated with increased cancer risk.
- Trial name
- HPB70+ (NCT06999512)
- Testing
- Comprehensive Geriatric Assessment
- Where
- 12 sites in France
- Volunteers
- 526 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma
Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma
Extrahepatic cholangiocarcinoma (eCCA) is a rare and aggressive cancer with poor prognosis. ECCA can be further subcategorised in perihilar and distal cholangiocarcinoma (pCCA and dCCA).
- Conditions
- Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma, Distal Cholangiocarcinoma, Resectable
- Trial name
- NEODISCO (NCT06923475)
- Testing
- Pembrolizumab, Gemcitabine, Cisplatin
- Where
- Netherlands
- Volunteers
- 150 people
- Sponsor
- Amsterdam UMC, location VUmc
Hilar Cholangiocarcinoma
Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Hilar Cholangiocarcinoma
The purpose of this study is to compare the adequacy of unilateral endoscopic biliary drainage using metallic stent with plastic stent in unresectable, complex, hilar, cholangiocarcinoma and cost analysis.
- Trial name
- NCT00721175
- Testing
- biliary stent (self expandable metallic stent), PS
- Where
- Thailand
- Volunteers
- 108 people
- Sponsor
- Khon Kaen University
Gallbladder Cancer, Hilar Cholangiocarcinoma
Toripalimab Combined With Capecitabine as Postoperative Adjuvant Therapy for Patients With Resectable Advanced Extrahepatic Biliary Tract Cancer
This is a randomized controlled study to evaluate the efficacy and safety of toripalimab plus capecitabine as postoperative adjuvant therapy for patients with resectable advanced extrahepatic biliary tract cancer.
- Conditions
- Gallbladder Cancer, Hilar Cholangiocarcinoma, Distal Cholangiocarcinoma
- Trial name
- NCT06717464
- Testing
- Capecitabine, Toripalimab
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Perihilar Cholangiocarcinoma, Klatskin Tumor
Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma
This is multicentric, single-arm, observational, investigator-drive study investigating the efficacy of liver transplantation after successful downstaging/disease control of unresectable perihilar cholangiocarcinoma using…
- Trial name
- pCOLA (NCT06986486)
- Where
- Italy
- Volunteers
- 8 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Liver Cancer, Liver Metastases
DRAGON Registry - International Multicenter Registry and Medical Image Bank for Patients With Primarily Unresectable Liver Cancer or Liver Metastases That Underwent Combined Portal and Hepatic Vein Embolization (PVE/HVE) to Increase Future Liver Remnant Before Resection.
The DRAGON registry aims to collect data on combined portal and hepatic vein embolization (PVE/HVE) for liver tumors, a technique expected to enhance liver regeneration compared to standard PVE.
- Trial name
- NCT07717437
- Where
- 31 sites in United States, Australia and 11 more
- Volunteers
- 350 people
- Sponsor
- Maastricht University Medical Center
Biliary Tract Cancer, Portal Vein Embolization
Effect of PVE on Surgical Outcomes and Long-term Survival in Perihilar Cholangiocarcinoma
Portal vein embolization is often recommended to reduce the risk of postoperative liver failure and mortality. In this retrospective cohort study, researchers investigated the effect of portal vein embolization in patients with…
- Trial name
- NCT06222619
- Testing
- Potal vein embilization
- Where
- South Korea
- Volunteers
- 136 people
- Sponsor
- Seoul National University Hospital
Cholangiocarcinoma, Hilar
Impact of Vascular Resection on Survival and Postoperative Outcomes in Patients With Hilar Cholangiocarcinoma: A Retrospective Study
Hilar cholangiocarcinoma is a highly aggressive malignancy, and surgical resection remains the only potentially curative treatment.
- Trial name
- NCT07311798
- Testing
- No Intervention: Observational Cohort
- Volunteers
- 300 people
- Sponsor
- Yongjun Chen